CA-SYNACK
13.6.2019 15:02:06 CEST | Business Wire | Press release
The debate on how we should best use Artificial Intelligence is ongoing, but no one can argue against its benefits when used to augment human work. Take self-driving cars: when Artificial Intelligence is used alongside humans, it provides features like improved safety and predictive driving. The same is true in cybersecurity; we will always need the creativity of human intelligence to beat the human adversary. However, we can also augment those humans with smart technology to help make them more effective, cover a wider attack surface, and speed up their time to find and fix vulnerabilities. Synack, the trusted leader in crowdsourced security, has just launched the industry’s first cybersecurity platform to integrate crowdsourced human intelligence augmented with artificial intelligence to help security teams work smarter, not harder, to protect digital assets continuously and at scale.
The impact? Intelligence that helps security teams find and fix vulnerabilities faster and build more secure code.
The stakes are high - cybercrime is predicted to cost the world $6 trillion annually by 2021- and human capital to protect the cybersphere is lacking; 3.5 million cybersecurity jobs are predicted to go unfilled by 2021 (Cybersecurity Ventures).
“While humans can’t scale, machines can’t think. More than 80% of the vulnerabilities that our Synack Red Team find in our clients’ assets aren’t detected by a scanner. We will always need the creativity of human intelligence. But to scale at the pace of the threats, we need to automate wherever possible and keep building technology to test ‘smarter’,” Dr. Mark Kuhr, Synack CTO and co-founder said.
Synack’s industry-leading cybersecurity Platform 2.0 delivers a smarter, more efficient security test through the use of smart platform technology and new product, SmartScan. Together, the platform’s new features and advanced technology seamlessly orchestrate the optimal combination of human and machine intelligence for more effective, efficient security on a 24/7/365 basis. SmartScan helps security teams increase their attack surface coverage and gain new insight by continuously scanning for suspected vulnerabilities and engaging the company’s crowdsourced network of ethical hackers to validate them. The augmented intelligence offered by Synack’s “smart” Crowdsourced Security Platform, if applied to all penetration testing, would add 4x more efficiency to security teams.
Additional benefits of Synack’s Crowdsourced Security Platform to security teams include:
- Noise Reduction: 99.98% of total noise is reduced by leveraging Synack SmartScan in combination with Synack Red Team crowdsourced vulnerability triage and patch verification services.
- Higher Value: The latest version of Synack’s platform with augmented intelligence increases the ROI of Synack’s original offering by over 50%. Customers will see a 159% ROI with the Synack Crowdsourced Security Platform in comparison to a traditional penetration test. And if comparing the Synack platform to a traditional scanner, they will get a 262% ROI. If deployed universally across application security testing, SmartScan would add ~$3B in security value back to the market.
In addition to SmartScan, Synack’s Crowdsourced Security Platform 2.0 includes other new and enhanced features; Apollo, a machine learning and automation engine that optimizes the integration of humans and technology, superior analytics and reporting, and LaunchPoint+, a secure testing gateway with added researcher endpoint control and enhanced workspaces to support privacy for highly regulated environments. Synack Red Team researchers said they were “happy with the [LaunchPoint+] concept”, “a fan of the increased bandwidth”, and could “definitely see myself using this a lot” in response to Synack launching the only crowdsourced security testing with endpoint control baked into the platform.
About Synack
Synack, the most trusted crowdsourced security platform, delivers continuous and scalable penetration testing with actionable results. The company combines the world's most skilled and trusted ethical hackers with AI-enabled technology to create an efficient and effective security solution. Headquartered in Silicon Valley with regional offices around the world, Synack protects leading global banks, federal agencies, DoD classified assets, and close to $1 trillion in Fortune 500 revenue. Synack was founded in 2013 by former US Department of Defense hackers Jay Kaplan, CEO, and Dr. Mark Kuhr, CTO. For more information, please visit www.synack.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190613005222/en/
Contact:
Ellie McCardwell, Synack Communications press@synack.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom